Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP
Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP
Biodexa Pharmaceuticals (NASDAQ:BDRX) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.
Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion
Basal Cell Nevus Syndrome Market Growth Accelerates with Novel Therapies and Clinical Developments | DelveInsight